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Abstract
PI3K plays a key role in cellular metabolism and cancer.
Using a mass spectrometry–based metabolomics platform, we
discovered that plasma concentrations of 26 metabolites,
including amino acids, acylcarnitines, and phosphatidylcho-
lines, were decreased in mice bearing PTEN-deﬁcient tumors
compared with non–tumor-bearing controls and in addition
were increased following dosing with class I PI3K inhibitor
pictilisib (GDC-0941). These candidate metabolomics biomar-
kers were evaluated in a phase I dose-escalation clinical trial of
pictilisib. Time- and dose-dependent effects were observed in
patients for 22 plasma metabolites. The changes exceeded
baseline variability, resolved after drug washout, and were
recapitulated on continuous dosing. Our study provides a link
between modulation of the PI3K pathway and changes in the
plasma metabolome and demonstrates that plasma metabo-
lomics is a feasible and promising strategy for biomarker
evaluation. Also, our ﬁndings provide additional support for
an association between insulin resistance, branched-chain ami-
no acids, and related metabolites following PI3K inhibition.
Mol Cancer Ther; 15(6); 1412–24. 2016 AACR.
Introduction
The successful incorporation into the Pharmacologic Audit
Trail of pharmacodynamic biomarkers can signiﬁcantly
increase the scientiﬁc rigor, decision-making reliability, and
hypothesis-testing power in drug development and in partic-
ular help mitigate the risk of attrition by conﬁrming target
engagement and informing key decisions regarding optimal
dose and schedule (1). In preclinical studies in oncology, solid
tumor samples can readily be obtained from mice bearing
human tumor xenografts to evaluate the effects of drugs. In
the clinical situation where few patients have accessible tumor,
this is challenging with pre- and posttreatment biopsies typi-
cally obtained in the best-case scenarios (2). Consequently,
biomarkers are often derived from surrogate tissues, for exam-
ple platelet-rich plasma or blood mononuclear cells, which can
be obtained in a minimally invasive way (3, 4). In patients with
metastatic disease, circulating tumor cells may be obtained but
they are few and not systematically amenable to studies eval-
uating target engagement (5). Imaging technologies are very
appealing and noninvasive but remain expensive and difﬁcult
to deploy across multiple centers (6).
We hypothesized that circulating metabolites may present an
attractive strategy to assess biomarker modulation in early phases
of clinical drug development. As aminimally invasive assessment,
plasma metabolomic analysis has the potential to complement
direct tumoral measurements and, particularly where cancer
biopsies are unavailable, can report on the integrated output of
multiple systems including sites of disease. There is no doubt that
the signatures will include output from both normal tissues and
cancers. However, given the increasing recognition that there is in
fact a key bidirectional interplay between the two, this could be
considered an advantage. Moreover, we reasoned that the PI3K
axis (which is a keymediator of cellular metabolism) represents a
desirable test system to evaluate this approach (7). It is thought to
function as a critical logic gate with a nutrient-sensing role and
controls the rate of metabolic processes including fatty acid
synthesis, b-oxidation, oxidative phosphorylation, and glycolysis
(8, 9). This pathway is signiﬁcantly associated with disordered
metabolism, including insulin resistance, and is modulated by
antidiabetic interventions (10, 11). The presence of germline
PTEN mutations has been linked with constitutively increased
insulin sensitivity and glucose tolerance inmice and humans (12,
13). There are thus strong a priori rationales for the study of the
PI3K pathway to evaluate the potential of plasma metabolomics
as a marker of target engagement in clinical studies. Multiple
agents are in development that target key mediators of the PI3K
pathway; among them, pictilisib (GDC-0941,Genentech Inc.) is a
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potent and selective pan-class I inhibitor of PI3K that is currently
being assessed in randomized phase II clinical trials (14–20).
Using liquid chromatography mass spectrometry (LC-MS), we
implemented a nontargeted exploratory screen for plasma meta-
bolites exhibiting consistent changes across genetic and pharma-
cologic perturbations of the PI3K pathway in mouse models. We
next evaluated the identiﬁed biomarker candidates in a dose-
escalation clinical trial of pictilisib, seeking dose- and time-
dependent changes in patients with advanced cancers following
drug administration. The conﬁrmation of plasma metabolite
changes in patients undergoing pharmacologic inhibition of PI3K
demonstrates the feasibility and promise of this approach for
minimally invasive biomarker development. The metabolite
changes we observed are consistent with the development of an
insulin resistance phenotype following treatment with a pan-class
I PI3K inhibitor.
Materials and Methods
The experimental workﬂow is presented in Fig. 1A. In the
exploratory preclinical screening studies, we compared plasma
from: (i) tumor-bearing PTEN (þ/) C57BL/6 euthymic mice
with non–tumor-bearing wild-type littermate controls and (ii)
athymic mice inoculated subcutaneously with or without PTEN
(/) U87MG glioblastoma or PC3 prostate human tumor
xenografts (21). Some of the mice were treated with pictilisib
(100 mg/kg) or vehicle controls at 2, 4, 8, and 24 hours post-
dosing. We compared the effects in plasma and tumor of another
chemically distinct oral pan-class I PI3K inhibitor (buparlisib)
with those for pictilicib at 8 hours following a single dose.We also
determined plasma metabolite proﬁles of athymic mice bearing
U87MG tumor xenografts dosed with vehicle or a representative
cytotoxic agent (carmustine; BCNU).
At the subsequent clinical evaluation stage, within the frame-
work of a phase I dose-escalation trial, we ﬁrst monitored the
levels of the candidate plasma metabolite biomarkers on two
separate days within a 2-week screening window, prior to
treatment, to deﬁne baseline levels. This was followed by
determining the plasma metabolite changes, relative to pre-
treatment baseline, at 2, 8, and 24 hours posttreatment with
different dose levels of pictilisib following oral administration
of an initial single dose on day 1. A longitudinal study was then
carried out following continuous once-daily oral dosing of
pictilisib from day 8 in patients treated at the maximally
Figure 1.
A, experimental workﬂow. B, schema illustrating once-
daily dosing schedule of pictilisib (each arrow
representing a dose administered) with the plasma
sampling schedule formetabolomic analysis summarized
in the sub-table.
Plasma Metabolome Changes in Response to PI3K Inhibition
www.aacrjournals.org Mol Cancer Ther; 15(6) June 2016 1413
tolerated dose (or higher) of pictilisib. Plasma metabolites were
assessed predose and at 1 hour postdose on day 8 and predose
and at 2, 8, and 24 hours on day 15.
Preclinical mouse models
All animal experiments were conducted in accordance with
local and United Kingdom National Cancer Research Institute
guidelines (22). Female mice with heterozygous (þ/) PTEN
knockout (ref. 23; n ¼ 5) on the C57BL/6 background and 25-
week-old age-matched wild-type littermates (n ¼ 6) were bled
synchronously in the same experiment. To generate the tumor
xenograft–bearing models, 2 million human cancer cells were
injected subcutaneously bilaterally into the ﬂanks of NCr athymic
mice of 6 to 8 weeks of age, bred in-house; PC3 human prostate
cancer cells and U87MG human glioblastoma cells were admin-
istered into male and female mice, respectively. Cell lines were
obtained from ATCC in 2006 and used within 6 months of
purchase. Authentication of the cell lines was subsequently per-
formed in-house. Cell lines were analyzed by short tandem repeat
(STR) proﬁling. Polymorphic STR loci were ampliﬁed using a PCR
primer set. The PCR product (each locus being labelled with a
different ﬂuorophore) was analyzed simultaneously with size
standards using automated ﬂuorescent detection. The number of
repeats at 7 to 10 different loci was used to deﬁne the STR proﬁle
and this was cross-referenced with online databases to conﬁrm
authenticity.
During the course of the experiment, food pellets (Certiﬁed
Rodent Diet 5002, Labdiet) and water were available ad libitum.
Dosing of each drug and its respective vehicle control was
undertaken synchronously in the same experiment when
tumors were well-established and measured approximately 8
to 10 mm in diameter. Carmustine was prepared in 5% ethanol
and 0.5% sterile saline, pictilisib, or buparlisib in 10% DMSO,
5% Tween 20, and 85% sterile saline. Compounds were dosed
in 0.1 mL/10 g body weight of vehicle once or twice daily
(carmustine intraperitoneally at 20 mg/kg; pictilisib by oral
gavage at 100 mg/kg; buparlisib by oral gavage at 60 mg/kg);
these represented biologically active, well-tolerated doses asso-
ciated with modulation of known downstream pharmacody-
namic biomarkers of PI3K inhibitors (17). Control animals
received an equivalent volume of appropriate vehicle. Blood
samples were collected into bottles using sodium heparin as
anticoagulant at 2, 8, and 24 hours post-drug administration.
The samples were centrifuged at 13,000 rpm for 2 minutes and
then transferred onto dry ice; the entire process from collection
to storage in dry ice took less than 5 minutes per sample. Three
to six mice were used for each time point per treatment.
Following completion of the entire experiment, the samples
were stored at 80C until further analyses.
Phase I dose-escalation clinical trial of pictilisib
Plasma samples for metabolomic analysis were obtained
from 41 patients with advanced cancers treated at The Royal
Marsden NHS Foundation Trust (London, United Kingdom)
in a phase I study of pictilisib with a standard 3 þ 3 dose-
escalation design (24). Pictilisib was administered orally
on day 1, followed by a 1-week washout, and dosing was
once-daily on either a 21- or 28-day dose schedule every 28
days. The assessed dose levels ranged from 45 to 450 mg [45 mg
(n ¼ 2), 60 mg (n ¼ 4), 80 mg (n ¼ 3), 100 mg (n ¼ 4), 245 mg
(n ¼ 1), 330 mg (n ¼ 16), 340 mg (n ¼ 7), 400 mg (n ¼ 1),
450 mg (n ¼ 3)]. In this study, the maximal tolerated dose was
330 mg administered once daily (20). Of 35 patients with
RECIST-measurable disease in whom metabolomic analysis
was undertaken, one achieved a partial response, 28 achieved
stable disease, and 6 sustained progressive disease (20). Study
duration in this cohort of patients ranged from 7 to 288 days.
Notably, there was marked heterogeneity in the primary tumor
type. For all dose levels assessed in this study, metabolomic
samples were collected pre-dose and 2, 8, and 24 hours post-
dose on day 1. In 17 patients treated with pictilisib at dose
levels 330 mg, once daily, samples were collected at the
following additional time points following a protocol amend-
ment: baseline at screening within 2 weeks prior to day 1, pre-
dose, and 1 hour post-dose on day 8; and pre-dose and 2, 8, and
24 hours post-dose on day 15. All patients were fasted for at
least 2 hours prior to each sampled time point but were
permitted water ad libitum. Plasma was separated from blood
(using sodium heparin as anticoagulant) following centrifuga-
tion at 1,500  g for 15 minutes at 4C; it was then stored at
80C until further analyses. The schedule of sample collection
is presented in Fig. 1B. Non-mandated immunohistochemical
analysis including phospho-AKT (Ser473) of tumor biopsies was
undertaken but these were limited in number and graded on a
semiquantitative scale. The electrochemiluminescense-based
assay of phospho-AKT (Luminex xMAP; Luminex Corp.) of
surrogate platelet-rich plasma was only conducted late in the
trial at the dose expansion phase. These limited our ability to
perform exploratory assessments of their relationship with the
observed metabolomic changes and additionally highlight
challenges in performing pharmacodynamic assessments in
phase I trials. At dose levels 100 mg, plasma was obtained
pre-dose and at 1 hour after dose on cycle 1 day 1 for analysis of
glucose and insulin levels. Estimates of insulin resistance were
derived on the basis of the Homeostasis Model Assessment
model (25). Non-mandated whole-body 18FDG-PET scans were
performed at baseline and 1 to 4 hours after dose between day
22 and the end of cycle 1. In all, 23 and 13 respective patients
who underwent metabolomic analysis also undertook glucose/
insulin and 18FDG-PET studies. All aspects of the study were
conducted in accordance with the Declaration of Helsinki and
the International Conference on Harmonization Good Clinical
Practice Guidelines. Written informed consent was obtained
from all participants.
Plasma metabolomics analysis
Nontargeted LC-MS metabolomics was initially used in the
preclinical screen as described previously (26); signiﬁcant changes
in plasma metabolites were identiﬁed. To follow-up and conﬁrm
these preliminary ﬁndings, we carried out targeted, quantitative
metabolomic analysis by electrospray ionization tandem MS
using the AbsoluteIDQ p180 Kit (Biocrates Life Sciences AG);
results from the conﬁrmatory, quantitative platform are presented
in this report. Samples were anonymized and analyses were
carried out on a Waters Acquity H-class UPLC coupled to Xevo
TQ-S triple-quadrupole MS/MS System (Waters Corporation).
Quantiﬁcation of the metabolites of the biological sample was
achieved by reference to appropriate internal standards. The
method conforms with the United States Food and Drug Admin-
istration Guidelines `Guidance for Industry – Bioanalytical Meth-
od Validation (May 2001)', providing proof of reproducibility
within a given error range.
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Data analysis
The analytic process to derive metabolite concentrations was
performed using the MetIDQ software package. The data matrix
obtained was subsequently subjected to multivariate analysis
using SIMCA v.13 software (MKS Umetrics AB); metabolite
features that were differentially expressed between deﬁned
groups of mice: (i) PTEN (þ/) mice versus wild-type litter-
mates; (ii) PC3-bearing versus non–tumor-bearing mice; (iii)
U87MG-bearing versus non–tumor-bearing mice; and (iv) pic-
tilisib-treated (100 mg/kg) versus vehicle control-treated mice
bearing PC3 prostate tumors or U87MG glioblastoma. Meta-
bolites responsible for changes were identiﬁed using orthogo-
nal partial least-square discriminant analysis (OPLS-DA; ref. 27)
with a threshold of variable importance in the projection (VIP)
value >0.8. To pass the exploratory preclinical screen, a metab-
olite was required to change consistently across both xenograft-
bearing mouse models treated with pictilisib (passing the
OPLS-DA ﬁlter) and at least one other preclinical model
involving the transgenic PTEN (þ/) or PTEN-null tumor
xenograft-bearing mice (compared with wild-type and non–
tumor-bearing littermates, respectively) with no contradictory
change in any other model. Permutation analysis was carried
out for model validation. Heatmaps were generated using the
concentration changes relative to vehicle control animals at
each time point. In the clinical study, changes relative to
pretreatment baseline levels on day 1 were calculated for each
patient across all time points; the geometric mean, associated
95% conﬁdence intervals and P values (H0, no different
between pre- and posttreatment levels) of relative change were
estimated for each time point and dose range [low, 45–60 mg
(n ¼ 6); mid: 80–245 mg (n ¼ 8); high: 330–450 mg (n ¼ 27)].
For unsupervised multivariate analysis, principal component
analysis (PCA) was undertaken using SIMCA v.13 software. In
addition, the SPSS program (v.21) and GraphPad Prism (v.6)
were used for all other statistical analyses. All P values pre-
sented are two-sided and values <0.05 were considered statis-
tically signiﬁcant.
Results
Preclinical models
Mice with PTEN-deﬁcient tumors have distinct plasma metabolite
proﬁles. At 8 weeks of age, no signiﬁcant differences were
observed in the plasma metabolite proﬁle between genetically
engineered PTEN (þ/) mice with no observable macroscopic
tumors compared with wild-type littermates. At 25 weeks, pal-
pable tumors, splenomegaly, and thymic enlargements were
observed in the PTEN (þ/) mice. Using OPLS-DA, the con-
centrations of 53 plasma metabolites were found to be signif-
icantly decreased in PTEN (þ/) transgenicmice comparedwith
wild-type littermates.
In addition, when mice harboring human tumor xenografts
were compared with non–tumor-bearing littermates, a decrease
was observed in the levels of 60 and 17 plasmametabolites for the
PTEN-negative PC3 prostate and U87MG glioblastoma models,
respectively. The overlap of the changes seen in the human tumor
xenografts and the PTEN-depleted transgenic mouse tumors is
illustrated in Fig. 2A. Twelve plasmametaboliteswere consistently
altered across all three animalmodels, with reductions seen in the
PI3Kpathway–aberrant tumor-bearingmice;metabolites affected
included amino acids, acylcarnitines, andphospholipids.Wenote
that the greatest overlap was between the PTEN-depleted versus
wild-type littermates and the PC3 tumor–bearing versus non–
tumor-bearing comparison. Regardless of the number of plasma
metabolites identiﬁed in each comparison, the majority of
changes in each case were common to the three models. Of note,
high degrees of separation between the experimental (tumor-
bearing, transgenic, or treated animals) and the relevant control
groups were observed in the OPLS-DA, with all R2 > 0.8 andQ2 >
0.6 (representing the explained variance and predictive capability
in the internal cross-validation, respectively).
In contrast to the number of metabolites noted above showing
decreased plasma levels, only a few metabolites across the panel
assessed were elevated in the xenograft tumor-bearing mice and
none was signiﬁcantly elevated in the PTEN-depleted model.
Figure 2.
Venn diagrams showing the overlap in
plasma metabolites between
preclinical animal models. A, PTEN
þ/ (depleted) versus wild-type
littermates and athymic mice bearing
PTEN-null human PC3 prostate
carcinoma or U87MG glioblastoma
xenografts compared with non–
tumor-bearing age-matched controls.
B, treatment with pictilisib versus
vehicle in PC3- and U87MG-bearing
mice. C, overlap between changes in
all 3 models in A and those common to
both models in B. Metabolites that
were further evaluated in the clinical
setting are enclosed by a thick black
line. Tx, treatment.
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Potent and speciﬁc pharmacological inhibition of class I PI3K using
pictilisib is associated with changes in the plasma metabolome. We
sought to examine the circulating metabolite changes at doses of
pictilisib inhibiting the phosphorylation of AKT Ser473 over 24
hours in platelet-rich plasma (17). OPLS-DA of the comparisons
between plasma metabolites in pictilisib (at 100 mg/kg) and
control vehicle-treated mice revealed an increase in the concen-
trations of 49 and 32plasmametabolites inmice bearing PC3 and
U8MG tumors, respectively. Of these, 28 metabolites were com-
mon to both models (Fig. 2B). Moreover, these metabolites were
similarly increased in mice bearing U87MG human tumor xeno-
grafts treated with 100 mg/kg GDC-0941 or 60 mg/kg buparlisib
(Supplementary Fig. S1). When these pictilisib treatment–related
changes were compared with those illustrated in Fig. 2A, 10
plasmametabolites were observed to exhibit variations consistent
across all 5 models: 13 metabolites in 4 of 5 models and 3
metabolites in 3 of 5 models.
On thebasis of these data, a panel of 26plasmametaboliteswas
selected for further clinical evaluation. The relevant changes
observed in this panel of 26metabolites across the variousmodels
along with their patterns of overlap are summarized in Fig. 2 and
Supplementary Table S1.
The plasma concentrations of 6 of 9 essential amino acids
(histidine, phenylalanine, threonine, valine, isoleucine, and tryp-
tophan)were signiﬁcantly decreased in the genetically engineered
PTEN (þ/) tumor–bearing animals and subsequently increased
following treatment with pictilisib in these mice. The levels of
nonessential amino acids, including asparagine, citrulline, gluta-
mate, and serine, were similarly decreased in the tumor-bearing
animals and increased following treatment with pictilisib in
tumor-bearing mice. The concentrations of acylcarnitines (with
the following acyl side chains: C3, C5, C16, C14:2-OH, C16:1-
OH, C18, C18:1, and C18:1-OH) were lower in the plasma of
PTEN (þ/) animals and/or PC3-bearing mice compared with
control animals and in addition were increased following picti-
lisib administration in both PC3- and U87MG tumor–bearing
mice. Signiﬁcant changes in phosphocholine metabolism were
observedwith lysophosphatidylcholine C18:1, C20:3, andC20:4,
acyl-acyl phosphatidylcholine C36:0, and acyl-alkyl phosphati-
dylcholines C40:1, C42:3, and C42:4 decreased in at least one
tumor-bearingmodel and increased followingpictilisib treatment
of tumor-bearing mice.
Thus, following the administration of a single dose of pictilisib
at doses where AKT phosphorylation is inhibited (17), the
observed increase in the plasma concentrations of the candidate
biomarkers in both tumor-bearing models represented a reversal
of changes observed in the presence of PTEN-deﬁcient tumors
(Fig. 3). The posttreatment changes were generally greater in the
PC3-bearingmice, occurredmainly after 4hours, andpersisted for
up to 24 hours ormore post-dose (Fig. 3). Themetabolite changes
observed in plasma from U87MG-bearing mice following treat-
ment with pictilisib were mirrored following treatment with
buparlisib (Supplementary Fig. S1).
In contrast to pictilisib treatment of tumor-bearing mice, there
was a general trend of reduction, rather than an increase, of the
metabolites following administration of the PI3K inhibitor to
non–tumor-bearing mice. Of note, a transient and slight increase
in plasma levels of amino acids was followed by a reduction in
their levels from 4 to 6 hours post-dose.
The metabolite changes described above are represented in the
heat map in Fig. 3A. Taken together, the data deﬁne a set of
changes in the plasma metabolome that are responsive to genetic
and pharmacologic perturbation of the PI3K pathway.
The chemotherapeutic agent carmustine induces plasma metabolite
changes distinct from those following PI3K inhibition in U87MG
tumor–bearing mice. As an additional control, we additionally
investigated changes in the plasma metabolites described above
in U87MG tumor–bearing mice following treatment with car-
mustine as a chemotherapeutic clinical standard of care for
glioblastoma. The observed changes were different from those
in pictilisib-treated tumor-bearing mice. In the carmustine-
treated U87MG-bearing mice, 2 distinct groups of plasma
metabolite changes were observed: (i) the amino acids and
short chain acylcarnitines showed a reduction in level followed
by an increase at 8 hours post-dose; and (ii) the long-chain
acylcarnitines and phosphatidylcholines generally increased
acutely and then decreased from 4 hours post-dose (Fig. 3A).
The major differences in plasma metabolome changes for the
cytotoxic agent carmustine versus the selective PI3K inhibitor
pictilisib provide evidence in support of speciﬁcity for the effects
seen with the latter agent.
Baseline characteristics of participants in phase I dose-
escalation clinical trial of pictilisib
Plasma samples were obtained from 41 patients with advanced
cancer with no conventional treatment options who participated
in a dose-escalation clinical trial of pictilisib (20, 24). The treat-
ment dosing and plasma sampling schedules are summarized
in Fig. 1B. Modulation of mechanism-based pharmacodynamic
biomarkers, including phosphorylation of S6 ribosomal protein
and AKT as well as 18FDG-PET uptake, was observed at dose levels
80 mg once-daily (20, 24).
Clinical evaluation of candidate plasmametabolite biomarkers
For the 26 plasma metabolome biomarkers selected from the
nontargeted exploratory preclinical study described above, the
mean intrapatient coefﬁcient of variation in baseline clinical
plasma samples ranged from 7% to 47%. Apart from C14:2-OH
acylcarnitine and acyl-acyl phosphatidylcholine C36:0, all meta-
bolites had a mean coefﬁcient of variation of <20% (Supplemen-
tary Table S2). Further clinical evaluation was not carried out for
the 2 metabolites with high coefﬁcients of variation, leaving 24
metabolites that we pursued further.
Following single-dose pictilisib treatment on day 1, dose-
and time-dependent changes were observed in 22 of these 24
candidate biomarkers, with only C18 acylcarnitine and acyl-alkyl
phosphatidylcholine C42:4 not changing signiﬁcantly (Fig. 3B).
The maximal changes posttreatment were greater than baseline
variability for each of these metabolites (Supplementary Tables
S2–S4). Signiﬁcant changes were observed 2 hours post-dose in
13 of 24 metabolites and were detected only at doses of pictilisib
80mg. Thismodulation of circulating biomarker coincideswith
doses where inhibition of AKT phosphorylation Ser473 was
observed in platelet-rich plasma (20). The highest number and
themost signiﬁcant changes occurred at 8hours post-dosewith 19
of 24 candidate metabolites showing statistically signiﬁcant
changes; persistence of these changes was seen at 24 hours
post-dose for 18 metabolites. Only 3 metabolites demonstrated
signiﬁcant changes following administration of pictilisib in the
lowest dose range (<80 mg once-daily); these changes were
observed at 8 hours post-dose only. At 8 and 24 hours post-
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administration, the greatest frequency of statistically signiﬁcant
changes was associated with the highest dose range. The observed
changes were generally consistent with that seen in the pictilisib-
treated tumor-bearing mice, the only exception being the long
chain acylcarnitines for which a decrease was observed in patients
following pictilisib treatment. The latter changes were more
similar to those seen in the non-tumor-bearing as opposed to
the tumor xenograft-bearing mice. The various changes are sum-
marized in Figs. 3B and 4 and presented in Supplementary Table
S3. The levels of eachmetabolite relative to time 0 for each patient
is presented in Supplementary Table S5.
In 17 patients treated with pictilisib at doses 330 mg once-
daily, additional plasma samples were obtained on days 8 and 15
of the continuous dosing phase. Note that all patients received a
Figure 3.
A, heatmap of differences between transgenic PTEN-deﬁcient tumor–bearing mice compared with their normal PTEN wild-type littermates (change relative to
control) and changes across time in candidate plasma metabolite biomarkers following treatment with pictilisib or carmustine (relative to vehicle control)
in tumor- andnon–tumor-bearingmice. a, acyl; aa, acyl-acyl; ae, acyl-alkyl; Cx:y,where x is the number of carbons in the fatty acid side chain, y is the number of double
bonds in the fatty acid side chain; AC, acylcarnitine; DC, decarboxyl; M, methyl; OH, hydroxyl; PC, phosphatidylcholine. B, heatmap (at right with header
labeled "Human") of statistically signiﬁcant changes (relative to baseline) in plasma concentrations of metabolite biomarker candidates in patients treated in
the dose-escalation trial of pictilisib. Juxtaposed (at left with header labeled "Mouse") are changes seen in selected preclinical models as shown in A. Highlighted
in yellow are the dose levels of pictilisib at which modulation of mechanism-based pharmacodynamic biomarkers including phosphorylated S6 ribosomal
protein and AKT and 18FDG-PET were observed. a, acyl; aa, acyl-acyl; ae, acyl-alkyl; Cx:y, where x is the number of carbons in the fatty acid side chain, y is the
number of double bonds in the fatty acid side chain; AC, acylcarnitine; DC, decarboxyl; M, methyl; OH, hydroxyl; PC, phosphatidylcholine.
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single dose of pictilisib on day 1, followed by a 1-week drug
holiday; dosing recommenced on day 8 on a continuous once-
daily schedule. Importantly, following dosing on day 15, the
trends and directionality of pictilisib-induced metabolome
changes for the panel of 24 candidate metabolite biomarkers
were similar to those observed for day 1 dosing. To illustrate this,
plots of selected metabolites andmetabolite classes are presented
in Fig. 5, and detailed results of these analyses are provided in
Supplementary Table S4.
Of the panel of 24 metabolites, none exhibited a signiﬁcant
change from the original baseline concentration prior to recom-
mencement of pictilisib on day 8, indicating a return to baseline
Figure 4.
Percentage change relative to baseline of selected plasma metabolites at 2, 8, and 24 hours after pictilisib dosing in 41 patients treated at different dose
levels. Geometric means with 95% conﬁdence intervals are represented in the plots. PC, phosphatidylcholine; BCAA, branched chain amino acid; AAA,
aromatic amino acids.
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after drug washout. Just before dosing on day 15, only 4 meta-
bolites were signiﬁcantly different from baseline levels.
We conclude that for the phase I cohort of patients studied, we
demonstrated successful translation and validationof the targeted
panel of plasmametabolites responsive toPI3K inhibition thatwe
initially discovered in the preclinical nontargeted exploratory
screen.
Exploratory assessment of relationship between metabolite
changes with other pharmacodynamic and clinical parameters
Unsupervisedmultivariate analysis based on the 22-metabolite
signature revealed an association between higher dose levels,
longer study durations, greater insulin resistance with increase
in amino acid, and short-chain acylcarnitine levels but decrease in
SUVmax and levels of long chain acylcarnitines (Fig. 6).
Figure 5.
Percentage change relative to baseline of selected plasmametabolites at planned time points over 2weeks on pictilisib treatment in 17 patients treated at dose levels
330 mg once-daily. Geometric means with 95% conﬁdence intervals are represented in the plots. Other details are as indicated in the legend to Fig. 4.
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Discussion
In this study, we show that a panel of circulating metabolite
biomarkers we discovered for assessing target engagement in
experimental models have successfully translated to a phase I
clinical trial. Perturbations of the PI3K pathway induced either
by genetic or pharmacologic means resulted in changes in the
plasmametabolome, comprising amino acids, acylcarnitines, and
phosphatidylcholines. We show that the concentrations of 26
plasma metabolites were decreased in various mouse models of
PTEN-deﬁcient tumors and increased following treatment with
pictilisib (a potent and speciﬁc pan-class I inhibitor of PI3K) in
mice bearing PTEN-deﬁcient human prostate and glioblastoma
tumor xenografts. Excluding the 2 plasma metabolites with high
physiologic baseline variability, we found that 22 of 24 of the
identiﬁed plasma metabolome biomarker candidates exhibited
signiﬁcant dose- and time-dependent changes in response to
PI3K inhibition when evaluated in the dose-escalation phase I
clinical trial of pictilisib.
Although an increasing number of novel inhibitors of the
PI3K pathway are entering clinical trials, currently available
pharmacodynamic biomarkers are restricted by issues includ-
ing biomarker signal lability, risk of sampling complications,
limited sensitivity and throughput, high costs of the associ-
ated analytical methods, and lack of amenability to repeated
sampling (2). In this context, the present study provides a
general framework for the rational discovery of pharmacody-
namic plasma metabolite biomarkers. In the preclinical
exploratory stage, we generated a panel of PI3K-responsive
metabolomics plasma biomarker candidates from model sys-
tems that are genetically deﬁned and maintained under a well-
controlled laboratory environment. These metabolite biomar-
kers were subsequently assessed and conﬁrmed in the clinical
stage where time and dose dependencies of the candidate
metabolite biomarkers were carefully evaluated. The use of
a combination of orthogonal genetic and pharmacologic
preclinical pathway perturbation models to screen for mech-
anism-based metabolite candidates provided increased rigor,
decreasing the likelihood of false-positive leads, and also
reduced the size of the panel of potential metabolite biomar-
kers for subsequent targeted analysis. In addition, the chosen
LC-MS analytical platform is robust, reproducible and high
throughput; sample preparation for a 96-well plate takes
about 2 hours, and MS data acquisition is completed after
12 hours. This is on a background of generally increasing
affordability and uptake of LC-MS instrumentation in recent
years.
Importantly, the changes observed in the majority of metabo-
lites thatwediscovered in thepreclinical screenwere subsequently
conﬁrmed in a phase I clinical trial setting, providing conﬁdence
in the preclinical biomarker discovery strategy. Since an analyt-
ically validated, quantitative platform was used to generate abso-
lute concentrations of the assessedmetabolites, we were therefore
Figure 6.
PCA biplot comprising superimposed scatter and loading plots showing relationship between plasmametabolite changes (as x components), insulin resistance (IR),
study duration, and SUVmax (as y components) as well as dose of pictilisib (labeled for each observation; n ¼ 13 patients). Clustering of changes in levels of
BCAA and AAA, study duration, and insulin resistance is noted; these variables are broadly related to inverse changes in SUVmax and changes in long chain
acylcarnitines and lysophosphatidylcholine levels.
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able to compare the data obtained in preclinical models and
those in patients.
We and others have previously shown that the interpretation of
clinical metabolite pharmacodynamic data is challenging and
may be confounded by variables such as food and diurnal
variation (28–30). To circumvent these potential effects, we
carried out multiple clinical measurements including: (i) assess-
ment of baseline pretreatment variability in metabolites of inter-
est taken on two separate days; (ii) examination of the relation-
ship between metabolite changes and dose levels on day 1 of the
clinical trial; and (iii) comparison ofmetabolite concentrations in
patients treated at the maximal tolerated dose or higher. In
addition, plasma levels over 24 hours on day 15 following a
week of continuous once-daily oral dosing were compared with
concentrations on day 8 after 1-week washout after drug admin-
istration. In our clinical study of 41 patients, the majority (22 of
24) of our identiﬁed biomarker candidates demonstrated consis-
tent changes across these assessments, and the observed changes
posttreatment were signiﬁcantly greater than pretreatment base-
line variability (Supplementary Tables S2–S4). These effects
occurred at pictilisib doses for whichmechanism-based biomark-
er modulation (plasma glucose and insulin levels, phosphorylat-
ed S6 ribosomal protein and AKT, as well as 18FDG-PET uptake)
has already been observed in the clinical study (20). The concor-
dance of these clinical observations with our preclinical ﬁndings
increases the likelihood that the plasma metabolite changes that
we observed are genuinely associatedwith systemic PI3K pathway
modulation. Furthermore, an exploratory unsupervisedmultivar-
iate analysis including patients in whommechanism-based phar-
macodynamics was concurrently performed revealed associations
between insulin resistance, 18FDG-PET changes, and candidate
plasma metabolites. Importantly, these observations increased
our conﬁdence of the choice of the recommended phase II dose
schedule.
The present study has provided proof of feasibility for the use of
a broad, systems-based strategy, translating from mouse models
to a phase I clinical trial setting, to identify effects on the meta-
bolome. We identiﬁed numerous amino acids in the plasma,
including the branched chain (BCAA) and aromatic (AAA) amino
acids, along with the products of their catabolism, the short-chain
C3 andC5 acylcarnitines that were downregulated in the presence
of PTEN-depleted tumors. Moreover, we showed that these
changes were reversed by PI3K pathway inhibition using the
pan-class I PI3K inhibitor pictilisib. Importantly, elevated levels
of these plasma metabolites have been consistently associated
with insulin resistance, are predictive of the risk of developing
diabetes mellitus, and are highly responsive to anti-diabetic
interventions (31–35). Furthermore, numerous studies have
demonstrated a direct role of BCAA and AAA in contributing to
the development of insulin resistance. The infusion of amino
acids (particularly BCAA) into humans and animals has been
shown to lead to insulin resistance, accompanied by activation of
mTOR, S6K1, and phosphorylation of IRS-1 (36). Addition of
BCAA or AAA to culturedmuscle cells in vitro leads to activation of
mTOR and impairment of insulin-stimulated phosphorylated
AKT and glucose uptake (37). Amino acids such as leucine and
glutamate are also potent insulin secretagogues (38). To put our
metabolite ﬁndings into pharmacologic context, dose-dependent
hyperglycemia and hyperinsulinemia were reported in the phase I
clinical trials of pictilisib and buparlisib (20, 24, 39). The adverse
event of hyperglycemia was the dose-limiting toxicity of the latter
agent. The acute and chronic pharmacologic inhibition of the
PI3K pathway has been shown to impact differentially on
glucose homeostasis; speciﬁcally, chronic dosing of pan-class I
inhibitorswas associatedwith an attenuation of treatment-related
hyperglycemia but not insulin sensitivity (40, 41). Furthermore,
chronic genetic inhibition of p110a was found to protect mice
from age-related reduction in insulin sensitivity, glucose toler-
ance, and fat accumulation (42).
The increase in short-chain acylcarnitines that we observed is
consistent with the reported PI3K/AKT signaling and is linked to
suppression of b-oxidation via inhibition of carnitine palmitoyl-
transferase 1a (CPT1a) gene expression and a glucose-addicted
phenotype (8, 43). On the basis of this model, one would expect
an increase in CPT1a level following pharmacologic PI3K inhi-
bition andhence an increase in long-chain acylcarnitine levels.We
observed such changes consistently in both of the pictilisib-
treated human tumor xenograft mouse models studied here. This
has also been reported by others in human cancer cells treated in
vitro (43). However, contrary to expectations, a signiﬁcant
decrease in the plasma levels of these particular metabolites was
observed in humans, an effect that is similar to the changes we
observed in non–tumor-bearing mice following pictilisib treat-
ment. Lower levels of long-chain acylcarnitines (in contrast to
their C3 and C5 counterparts) have been linked to insulin
resistance and may partly explain our ﬁndings (34). The regula-
tion of plasma long-chain acylcarnitine level is complex and
reﬂects the balance between processes such as fatty acid synthesis
and hydrolysis and b-oxidation. The described differences
between murine and human mitochondrial b-oxidation of
long-chain fatty acids may also account for the differences that
we observed (44).
Our studies show a signiﬁcant increase in speciﬁc lysopho-
sphatidylcholines and phosphatidylcholine following treatment
with pictilisib in plasma and tumor. This is in contrast with
observations in glioblastoma cells by NMR where decreases in
total glycerophosphocholine and phosphocholine have been
reported largely supported by the decrease in choline kinase
(45, 46). However, other studies performed by 31P-NMR in breast
cancer models have reported an increase in these metabolites
attributed to increased levels of phospholipase A2 group 4A (47).
Lysophosphatidylcholine acyltransferase 1 (LPCAT1) has been
studied in colorectal, gastric, and prostate cancers (48–50) where
low plasma levels of these metabolites are associated with the
presence of cancer, supporting our preclinical ﬁndings. Lysopho-
sphatidylcholines enhance glucose-dependent insulin secretion
from pancreatic b-cells and inhibit insulin-induced AKT activa-
tion through protein kinase C a in vascular smooth muscle cells
(51, 52). Interestingly, the long-chain carnitines, lysophosphati-
dylcholine, and phosphatidylcholine that were signiﬁcantly
increased in our studies are even-chain. It has been shown that
the associated even-chain saturated fatty acids are positively
associated with diabetes mellitus, whereas odd-chain derivatives
are inversely associated with it (53).
We observed that the plasma levels of the vast majority of our
large panel of metabolites in the transgenic PTEN (þ/) mice
were considerably lower compared with wild-type littermates.
These changes showed a signiﬁcant overlap with plasma metab-
olite levels we determined in the presence of PTEN null human
tumor xenografts, especially the PC3 prostate carcinoma. Our
results are consistent with published clinical data on plasma
amino acids being reduced in a large series of patients with
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advanced cancer, although they are contradicted by data from
smaller studies (54, 55).We note also that themetabolite changes
were greater inmice harboring PC3 prostate carcinoma compared
with U87MG glioblastoma xenografts; pictilisib is a P-glycopro-
tein substrate and themarked difference in P-glycoprotein expres-
sion between the two xenografts (absent in the former andpresent
in the latter) may have contributed to this observation (56, 57).
While the assessment of plasma metabolomics in patients
cannot distinguish between tumor- and non–tumor-related
changes, it is interesting that the plasma metabolite changes that
we observed following pictilisib treatment between tumor- and
non–tumor-bearing animals were distinct. We propose that this
difference may be attributed to the presence of tissue with a
hyperactivated PI3K pathway in the former. PTEN-null human
tumor xenografts were chosen to increase the likelihood of
detecting pathway-related metabolic changes, that is, drug inhi-
bition of a hyperactivated pathway. Further follow-up studies are
now required to determine metabolome proﬁles in a wider range
of tumor models with different PI3K pathway activation status
and using various PI3K pathway inhibitory drugs and other
molecular targeted inhibitors.
In summary, using an analytically validated, highly sensitive,
high-throughput, LC-MS–based metabolomics approach, we
have identiﬁed distinct plasma metabolome changes that were
consistently altered across different preclinical tumor models in
which the PI3K pathway is activated by PTEN depletion. In the
clinical evaluation of the candidate pharmacodynamic plasma
metabolome biomarkers, time- and dose-dependent changes
were observed for the majority of the metabolites. These ﬁndings
suggest that under controlled conditions, plasmametabolomics is
a valid tool to assess biomarker modulation in early clinical
studies.
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